The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index; none of the 42 sources its claims cite is checked for support yet.
The TLQP-21 Peptide Activates the G-Protein-Coupled Receptor C3aR1 via a Folding-upon-Binding Mechanism
Open accessAbstract
SUMMARY TLQP-21, a VGF-encoded peptide is emerging as a novel target for obesity-associated disorders. TLQP-21 is found in the sympathetic nerve terminals in the adipose tissue and targets the G-protein-coupled-receptor (GPCR) Complement-3a-Receptor1 (C3aR1). So far, the mechanisms of TLQP-21-induced receptor activation remained unexplored. Here, we report that TLQP-21 is intrinsically disordered and undergoes a disorder-to-order transition, adopting an α-helical conformation, upon targeting cells expressing the C3aR1. We determined that the hot spots for TLQP-21 are located at the C-terminus, with mutations in the last four amino acids progressively reducing the bioactivity and, a single site mutation (R21A) or C-terminal amidation abolishing its function completely. Interestingly, the human TLQP-21 sequence carrying a S20A substitution activates the human C3aR1 receptor with lower potency compared to the rodent sequence. These studies reveal the mechanism of action of TLQP-21 and provide molecular templates for designing agonists and antagonists to modulate C3aR1 functions.
Overview
CoChat Summary
TL;DR
TLQP-21 is intrinsically disordered and folds into an α-helix upon binding C3aR1, activating the receptor. Its C-terminal residues, especially Arg21, are required for bioactivity, and human TLQP-21 has lower potency than rodent TLQP-21 at human C3aR1.
Key findings
- TLQP-21 cross-linked to a ~55 kDa protein corresponding to C3aR1 in 3T3L1 and CHO membranes; the C3aR1 antagonist SB290157 substantially reduced cross-linking. In β-arrestin recruitment assays at human C3aR1, EC50 values were C3a = 3.0 μM, mouse TLQP-21 = 10.3 μM, and human TLQP-21 = 68.8 μM.
- NMR showed TLQP-21 was unstructured in solution and in membrane-mimetic environments, but adopted α-helical chemical shifts when incubated with C3aR1-expressing 3T3L1 cells, wild-type splenocytes, and N38 cells; this transition did not occur with C3aR1-knockout splenocytes and was partially blocked by SB290157.
- In rat gastric fundus contraction, 3 μM TLQP-21 produced ~69% of the acetylcholine response, while C3a70-77 produced ~55%. TLQP-11 was inactive up to 10 μM; HFHH-10 gave ~3% at 3 μM, 62% at 6 μM, and 75% at 10 μM. P18A gave ~65% at 3 μM; P19A gave 19% at 3 μM and 35% at 6 μM; human TLQP-21 gave ~20% at 3 μM; R21A and C-terminal amidation abolished activity.
- TLQP-21 did not increase lipolysis alone but enhanced isoproterenol-induced lipolysis in 3T3L1 adipocytes; R21A did not potentiate isoproterenol-induced lipolysis or AMPK phosphorylation, although it still underwent the helical transition.
Methods
- Solid-state MAS NMR and solution NMR with 15N/13C-labeled TLQP-21 analogs, plus secondary structure prediction; peptide was incubated with 3T3L1, N38, wild-type or C3aR1-knockout splenocytes, with or without SB290157.
- Photoaffinity cross-linking using biotin-conjugated TLQP-21 with a benzophenone substitution, membrane preparations from 3T3L1 and CHO cells, and Western blotting; β-arrestin recruitment assay in HTLA cells transfected with C3aR1.
- Bioassays included rat gastric fundus contraction, truncated and Ala-scanning analogs, and lipolysis/AMPK Western blotting in differentiated 3T3L1 adipocytes; splenocytes were from BALB/cJ and C3aR1 knockout mice.
Limitations
- Stated: “A full understanding of the similarities in the mechanism of action of TLQP-21 and C3a is currently lacking.” The receptor concentration was unknown in NMR inhibitor experiments, so 5 μM SB290157 was used and only partial receptor saturation was observed.
- Evident from the text: no atomic structure of the TLQP-21–C3aR1 complex is reported; the α-helical bound conformation is inferred from NMR chemical shifts in cell preparations rather than a receptor-bound structure.
- Evident from the text: human versus rodent potency differences are described but not fully explained, and some conclusions rely on cell lines and heterologous assays.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 23 Not checked · 38 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the P18A mutant showed partial biological function with ~65% activity at 3μM.”
§ The TLQP-21 Peptide Activates the G-protein-coupled receptor C3aR1 via a Folding-upon-Binding Mechanism > RESULTS > Determination of the hot spots for TLQP-21 biological function
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“HFHH-10 induced a modest biological activity, with ~3% response at a concentration of 3μM, 62% at 6μM, and 75% at 10μM.”
§ The TLQP-21 Peptide Activates the G-protein-coupled receptor C3aR1 via a Folding-upon-Binding Mechanism > RESULTS > Determination of the hot spots for TLQP-21 biological function
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the spectrum of TLQP-PAR (Figure 4C) we detected two conformations of the peptide: one with chemical shifts corresponding to the unfolded peptide, and a weaker set matching the helical structure. These data indicate that there is only a partial saturation of the receptor on the adipocytes with the SB290157 inhibitor.”
- Also stated in: § DISCUSSION · plain
“can be inhibited upon treatment of 3T3L1 cells with a selective and competitive antagonist of the C3aR1 receptor”
§ The TLQP-21 Peptide Activates the G-protein-coupled receptor C3aR1 via a Folding-upon-Binding Mechanism > RESULTS > TLQP-21 undergoes a disorder-to-order transition upon binding C3aR1
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § DISCUSSION · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“does not have a strong tendency to associate with lipid bilayers”
- Also stated in: § DISCUSSION · plain
“does not assume an ordered conformation upon addition of helical-inducing environments”
§ The TLQP-21 Peptide Activates the G-protein-coupled receptor C3aR1 via a Folding-upon-Binding Mechanism > RESULTS > TLQP-21 undergoes a disorder-to-order transition upon binding C3aR1
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § DISCUSSION · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“C-terminal amidation abolishing its function completely”
- Also stated in: § Determination of the hot spots for TLQP-21 biological function · plain
“Upon C-terminal amidation, the TLQP-21 peptide is completely inactivated (Table 1)”
§ The TLQP-21 Peptide Activates the G-protein-coupled receptor C3aR1 via a Folding-upon-Binding Mechanism > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Determination of the hot spots for TLQP-21 biological function · plain
29 more claims
Create a free account to see all 61 claims and to verify the 38 references still open.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 10
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By mutating the Arg21 into Arg21 (R21A peptide) the resulting peptide is inactive [Cero et al., 2014, 2017; Doleen et al., 2017] that still preserves its ability to form α-helix in the presence of the C3aRl [Cero et al., 2014]”
From Clearance kinetics of the VGF-derived neuropeptide TLQP-21 (2018) · cites this paper as Cero et al., 2014
In the citing paper
“Based on reported biological results, this fragment is inactive at the C3aRl [Cero et al., 2014; Doleen et al., 2017].”
From Clearance kinetics of the VGF-derived neuropeptide TLQP-21 (2018) · cites this paper as Cero et al., 2014
In the citing paper
“This finding has important implication and suggests that the anti-obesity effect exerted by central [Bartolomucci et al., 2006] and peripheral [Cero et al., 2014] TLQP-21 injection are mediated by different mechanisms [Jiang et al, 2017].”
From Clearance kinetics of the VGF-derived neuropeptide TLQP-21 (2018) · cites this paper as Cero et al., 2014
In the citing paper
“Similar to C3a, the receptor activation residues are located at the very C-terminus of TLQP-21 [Cero et al., 2014]”
From Clearance kinetics of the VGF-derived neuropeptide TLQP-21 (2018) · cites this paper as Cero et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The TLQP-21 Peptide Activates the G-protein-coupled receptor C3aR1 via a Folding-upon-Binding Mechanism > RESULTS > TLQP-21 targets the C3aR1 receptor
“We found that the EC50 for mouse TLQP-21 is approximately 3 times lower than that of C3a and the EC50 for the human TLQP-21 is approximately 22 times lower than C3a”
§ The TLQP-21 Peptide Activates the G-protein-coupled receptor C3aR1 via a Folding-upon-Binding Mechanism > RESULTS > TLQP-21 targets the C3aR1 receptor
“EC50, C3a=3.0μM; mouse TLQP-21=10.3μM; human TLQP-21=68.8μM”
Citations
Cites
Electrostatics of nanosystems: Application to microtubules and the ribosome
Baker, N. A., Sept, D., Joseph, S., Holst, M. J., & McCammon, J. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181342398 · Cited by 7,172
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
VALE, W., SPIESS, J., RIVIER, C., & RIVIER, J. (1982) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198205000-00013 · Cited by 3,904
The Xplor-NIH NMR molecular structure determination package
Schwieters, C. D., Kuszewski, J. J., Tjandra, N., & Marius Clore, G. (2003) · Journal of Magnetic Resonance · doi:10.1016/s1090-7807(02)00014-9 · Cited by 2,369
Green, H., & Kehinde, O. (1975) · Cell · doi:10.1016/0092-8674(75)90087-2 · Cited by 1,360
Converting a Peptide into a Drug: Strategies to Improve Stability and Bioavailability
Adessi, C., & Soto, C. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867024606731 · Cited by 614
Combinatorial alanine-scanning
Morrison, K. L., & Weiss, G. A. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00206-4 · Cited by 443
Perspectives on NMR in drug discovery: a technique comes of age
Pellecchia, M., Bertini, I., Cowburn, D., Dalvit, C., Giralt, E., Jahnke, W., James, T. L., Homans, S. W., Kessler, H., Luchinat, C., et al. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2606 · Cited by 414
Adipsin Is an Adipokine that Improves β Cell Function in Diabetes
Lo, J. C., Ljubicic, S., Leibiger, B., Kern, M., Leibiger, I. B., Moede, T., Kelly, M. E., Chatterjee Bhowmick, D., Murano, I., Cohen, P., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.005 · Cited by 381
Gaboriaud, C., Juanhuix, J., Gruez, A., Lacroix, M., Darnault, C., Pignol, D., Verger, D., Fontecilla-Camps, J. C., & Arlaud, G. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307764200 · Cited by 362
Cited by
Coulthard, L. G., & Woodruff, T. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403068 · Cited by 285
Multiscale causal networks identify VGF as a key regulator of Alzheimer’s disease
Beckmann, N. D., Lin, W.-J., Wang, M., Cohain, A. T., Charney, A. W., Wang, P., Ma, W., Wang, Y.-C., Jiang, C., Audrain, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17405-z · Cited by 172
VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases
Quinn, J. P., Kandigian, S. E., Trombetta, B. A., Arnold, S. E., & Carlyle, B. C. (2021) · Brain Communications · doi:10.1093/braincomms/fcab261 · Cited by 139
Lin, W., Jiang, C. S., Sadahiro, M., Bozdagi, O., Vulchanova, L., Alberini, C. M., & Salton, S. R. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0584-15.2015 · Cited by 127
Self-citationThe role of complement system in adipose tissue-related inflammation
Vlaicu, S. I., Tatomir, A., Boodhoo, D., Vesa, Ș. C., Mircea, P. A., & Rus, H. (2016) · Immunologic Research · doi:10.1007/s12026-015-8783-5 · Cited by 101
El Gaamouch, F., Audrain, M., Lin, W.-J., Beckmann, N., Jiang, C., Hariharan, S., Heeger, P. S., Schadt, E. E., Gandy, S., Ehrlich, M. E., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-0357-x · Cited by 92
Gedam, M., Comerota, M. M., Propson, N. E., Chen, T., Jin, F., Wang, M. C., & Zheng, H. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167501 · Cited by 76
Akgün, E., Lunzer, M. M., & Portoghese, P. S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00323 · Cited by 69
Neuropeptides in Alzheimer’s Disease: An Update
Petrella, C., Certo, M. G. D., Barbato, C., Gabanella, F., Ralli, M., Greco, A., Possenti, R., & Severini, C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190503152555 · Cited by 60
Self-citationComplement in Neurologic Disease
Propson, N. E., Gedam, M., & Zheng, H. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-031620-113409 · Cited by 48
Cero, C., Razzoli, M., Han, R., Sahu, B. S., Patricelli, J., Guo, Z., Zaidman, N. A., Miles, J. M., O'Grady, S. M., & Bartolomucci, A. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.10.005 · Cited by 43
Self-citationComplement 3a receptor in dorsal horn microglia mediates pronociceptive neuropeptide signaling
Doolen, S., Cook, J., Riedl, M., Kitto, K., Kohsaka, S., Honda, C. N., Fairbanks, C. A., Taylor, B. K., & Vulchanova, L. (2017) · Glia · doi:10.1002/glia.23208 · Cited by 38
Self-citationKim, J., Bai, Y., Jayne, L. A., Abdulkader, F., Gandhi, M., Perreau, T., Parikh, S. V., Gardner, D. S., Davidson, A. J., Sander, V., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015110 · Cited by 32
Westacott, L. J., Humby, T., Haan, N., Brain, S. A., Bush, E., Toneva, M., Baloc, A.-I., Moon, A. L., Reddaway, J., Owen, M. J., et al. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.09.005 · Cited by 32
Han, J., & Zhang, X. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.653293 · Cited by 31
Functional profiling of the G protein-coupled receptor C3aR1 reveals ligand-mediated biased agonism
Rodriguez, P., Laskowski, L. J., Pallais, J. P., Bock, H. A., Cavalco, N. G., Anderson, E. I., Calkins, M. M., Razzoli, M., Sham, Y. Y., McCorvy, J. D., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105549 · Cited by 30
Self-citationA THP-1 Cell Line-Based Exploration of Immune Responses Toward Heat-Treated BLG
Deng, Y., Govers, C., ter Beest, E., van Dijk, A. D. J., Hettinga, K. A., & Wichers, H. J. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2020.612397 · Cited by 30
VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice
D’Amato, F., Noli, B., Angioni, L., Cossu, E., Incani, M., Messana, I., Manconi, B., Solinas, P., Isola, R., Mariotti, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142333 · Cited by 28
Complement C3aR signaling: Immune and metabolic modulation and its impact on Alzheimer's disease
Gedam, M., & Zheng, H. (2024) · European Journal of Immunology · doi:10.1002/eji.202350815 · Cited by 27
Thalamocortical axons regulate neurogenesis and laminar fates in the early sensory cortex
Monko, T. R., Rebertus, J., Stolley, J., Salton, S. R., & Nakagawa, Y. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2201355119 · Cited by 26
Peptide/Receptor Co-evolution Explains the Lipolytic Function of the Neuropeptide TLQP-21
Sahu, B. S., Rodriguez, P., Nguyen, M. E., Han, R., Cero, C., Razzoli, M., Piaggi, P., Laskowski, L. J., Pavlicev, M., Muglia, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.101 · Cited by 26
Self-citationSadahiro, M., Erickson, C., Lin, W., Shin, A. C., Razzoli, M., Jiang, C. S., Fargali, S., Gurney, A., Kelley, K. A., Buettner, C., et al. (2015) · Endocrinology · doi:10.1210/en.2014-1826 · Cited by 25
Self-citationKing, B. C., & Blom, A. M. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.12.009 · Cited by 25
Westacott, L. J., Haan, N., Evison, C., Marei, O., Hall, J., Hughes, T. R., Zaben, M., Morgan, B. P., Humby, T., Wilkinson, L. S., et al. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.08.215 · Cited by 25
Gopinath, T., & Veglia, G. (2018) · Methods · doi:10.1016/j.ymeth.2018.07.003 · Cited by 24
Self-citationVGF: a biomarker and potential target for the treatment of neuropathic pain?
Soliman, N., Okuse, K., & Rice, A. S. C. (2019) · PAIN Reports · doi:10.1097/pr9.0000000000000786 · Cited by 24
The VGF-derived peptide TLQP-62 modulates insulin secretion and glucose homeostasis
Petrocchi-Passeri, P., Cero, C., Cutarelli, A., Frank, C., Severini, C., Bartolomucci, A., & Possenti, R. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0313 · Cited by 23
Self-citationBrancia, C., Noli, B., Boido, M., Pilleri, R., Boi, A., Puddu, R., Marrosu, F., Vercelli, A., Bongioanni, P., Ferri, G., et al. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.023 · Cited by 22
Clearance kinetics of the VGF-derived neuropeptide TLQP-21
Guo, Z., Sahu, B. S., He, R., Finan, B., Cero, C., Verardi, R., Razzoli, M., Veglia, G., Di Marchi, R. D., Miles, J. M., et al. (2018) · Neuropeptides · doi:10.1016/j.npep.2018.06.003 · Cited by 21
Self-citationChanges in VGF and C3aR1 gene expression in human adipose tissue in obesity
Koc, G., Soyocak, A., Alis, H., Kankaya, B., & Kanigur, G. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06043-9 · Cited by 19
Cho, K., Jang, Y.-J., Lee, S.-J., Jeon, Y.-N., Shim, Y.-L., Lee, J., Lim, D.-S., Kim, D., & Yoon, S. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.111 · Cited by 19
Molteni, L., Rizzi, L., Bresciani, E., Possenti, R., Passeri, P. P., Ghé, C., Muccioli, G., Fehrentz, J., Verdié, P., Martínez, J., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00167 · Cited by 18
Self-citationRivolta, I., Binda, A., Molteni, L., Rizzi, L., Bresciani, E., Possenti, R., Fehrentz, J., Verdié, P., Martínez, J., Omeljaniuk, R. J., et al. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00041 · Cited by 16
Self-citationAkhter, S., Chakraborty, S., Moutinho, D., Álvarez-Coiradas, E., Rosa, I., Viñuela, J. E., Domínguez, E., García, Á. G., & Requena, J. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185176 · Cited by 15
The molecular mechanism of vgf in appetite, lipids, and insulin regulation
Benchoula, K., Parhar, I. S., & Wong, E. H. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105855 · Cited by 12
Evaluation of VGF peptides as potential anti-obesity candidates in pre-clinical animal models
Dalbøge, L. S., Jacobsen, J. M., Mehrotra, S., Mercer, A. J., Cox, N., Liu, F., Bennett, C. M., Said, M. Y., Tang‐Christensen, M., Raun, K., et al. (2020) · Peptides · doi:10.1016/j.peptides.2020.170444 · Cited by 11
TLQP-21 changes in response to a glucose load
Corda, G., Noli, B., Manconi, B., Brancia, C., Pellegrini, M., Naro, F., Olianas, A., Ferri, G., & Cocco, C. (2020) · Tissue and Cell · doi:10.1016/j.tice.2020.101471 · Cited by 11
de Araujo, A. D., Wu, C., Wu, K., Reid, R. C., Durek, T., Lim, J., & Fairlie, D. P. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00132 · Cited by 11
The molecular identity of the TLQP-21 peptide receptor
Sahu, B. S., Nguyen, M. E., Rodriguez, P., Pallais, J. P., Ghosh, V., Razzoli, M., Sham, Y. Y., Salton, S. R., & Bartolomucci, A. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03944-1 · Cited by 10
Self-citationDynamic of TLQP-peptides upon fasting
Noli, B., Brancia, C., Corda, G., Ferri, G., & Cocco, C. (2020) · Tissue and Cell · doi:10.1016/j.tice.2020.101368 · Cited by 10
Alqarni, S., & Alsebai, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032192 · Cited by 8
Molteni, L., Rizzi, L., Bresciani, E., Meanti, R., Fehrentz, J., Verdié, P., Omeljaniuk, R. J., Biagini, G., Locatelli, V., & Torsello, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01386 · Cited by 8
Embryonic ablation of neuronal VGF increases energy expenditure and reduces body weight
Jiang, C., Lin, W.-J., Sadahiro, M., Shin, A. C., Buettner, C., & Salton, S. R. (2017) · Neuropeptides · doi:10.1016/j.npep.2016.12.005 · Cited by 8
Chakraborty, S., Akhter, S., Requena, J. R., & Basu, S. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12541 · Cited by 6
TLQP-21 is a low potency partial C3aR activator on human primary macrophages
Li, X. X., Lee, J. D., Lee, H. S., Clark, R. J., & Woodruff, T. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1086673 · Cited by 6
A Novel Class of Complement 3a Receptor Agonists and Antagonists Derived from the TLQP-21 Peptide
Rodriguez, P., Pallais, J. P., He, R., Razzoli, M., McKee, J. L., Bock, H. A., McCorvy, J. D., Sham, Y. Y., DiMarchi, R., & Bartolomucci, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01177 · Cited by 5
Self-citationCui, J., Shen, F., Zhang, C., Fu, C., Zhu, J., & Zhuang, T. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156386 · Cited by 3
Mishra, S., Yadav, M. K., Dalal, A., Ganguly, M., Yadav, R., Sawada, K., Tiwari, D., Roy, N., Banerjee, N., Fung, J. N., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76518-z · Cited by 3
Berkowitz, S. H., Goldberg, Z., Golderman, V., Dori, A., Maggio, N., Devaux, J. J., & Stein, E. S. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70129 · Cited by 3
VGF is required for recovery after focal stroke
Gillis, H., Kalinina, A., Xue, Y., Yan, K., Turcotte-Cardin, V., Todd, M. A. M., Young, K. G., Lagace, D. C., & Picketts, D. J. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114326 · Cited by 3
Sahu, B. S., Razzoli, M., McGonigle, S., Pallais, J. P., Nguyen, M. E., Sadahiro, M., Jiang, C. S., Lin, W., Kelley, K. A., Rodriguez, P. J., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101781 · Cited by 2
Self-citationMoon, S.-A., Kim, J., Lee, Y., Cho, H. J., Choi, Y. J., Yoon, J. H., Kim, D., Che, X., Jin, X., Baek, I., et al. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01419-y · Cited by 2
Structure of neuroendocrine regulatory peptide‐2 in membrane‐mimicking environments
Park, O., Bang, J. K., Ryu, K., Hwang, E., Hong, K. S., Byun, Y., Cheong, C., & Jeon, Y. H. (2020) · Peptide Science · doi:10.1002/pep2.24206 · Cited by 2
Structure of AQEE-30 of VGF Neuropeptide in Membrane-Mimicking Environments
Park, O., Bang, J. K., Cheong, C., & Jeon, Y. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213953 · Cited by 2
The Pathways Involved in TLQP-62 Mediated Biological Functions
Akhter, M. S., & Arif, J. (2018) · JOURNAL OF ADVANCES IN BIOTECHNOLOGY · doi:10.24297/jbt.v7i1.6749 · Cited by 1
Mechanisms of the pro-lipolytic and anti-obesity effects of the VGF-derived peptide TLQP-21
Cero, C. (2015) · University of Minnesota Digital Conservancy (University of Minnesota)
Self-citationSassi, F. D. A. (2016) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-8238
Westacott, L. J. (2016) · ORCA Online Research @Cardiff (Cardiff University)
PHARMACOLOGICAL CHARACTERIZATION OF THE INTRACELLULAR SIGNALLING PATHWAYACTIVATED BY TLQP-21
Molteni, L. (2017) · BOA (University of Milano-Bicocca)
Investigating the Role of VGF and Its Associated Neuropeptides in Post-Stroke Recovery and Repair
Gillis, H. (2020) · uO Research (University of Ottawa) · doi:10.20381/ruor-25119
Peptide/Receptor Evolution Explains the Lipolytic Function of the Neuropeptide TLQP-21Preprint
Sahu, B. S., Han, R., Cero, C., Razzoli, M., Rodriguez, P. J., Nguyen, M. E., Piaggi, P., Pavličev, M., Muglia, L. J., Mahata, S. K., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3341735
Self-citationBasu, A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736550002.793571773
Yan, R. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738448428.793577747
de França, F. S. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2021.tde-04052022-155627
The role of the complement system in non-alcoholic fatty liver disease
Nguyen, V. D. (2024) · ORCA Online Research @Cardiff (Cardiff University)
Old and new evidence for neuropeptide involvemeint in alzheimer's disease
Severni, C., Petrella, C., Passeri, P. P., & Possenti, R. (2016) · Cineca Institutional Research Information System (Tor Vergata University)
Self-citationCharacterizing new conotoxin interactions with G protein-coupled receptors by using PRESTO-Tango
Akoa Mbida, A. (2025) · DiVA (Digitala Vetenskapliga Arkivet)
Nuclear magnetic resonance of membrane proteins–Advances and opportunities
Shin, K., Gopinath, T., & Marassi, F. M. (2026) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2026.103284
Self-citationForoutan, P., Lopez-Canovas, J. L., Mohammadi, F., Nasiri, K., & Amaro‐Gahete, F. J. (2026) · Physiology & Behavior · doi:10.1016/j.physbeh.2026.115405
Xie, Y., Wen, Y., Wen, X., Zhang, B., & Zhao, J. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48101053
Wu, D., Qiang, P., Xie, W., Wang, T. K., He, N., He, L., Zhang, D., Mirza, M., Ng, C.-F., & Li, B. (2026) · Serican Journal of Medicine · doi:10.17161/sjm.v3i4.26319
Metadata
- Authors
- Cero, C., Vostrikov, V. V., Verardi, R., Severini, C., Gopinath, T., Braun, P. D., Sassano, M. F., Gurney, A., Roth, B. L., Vulchanova, L., Possenti, R., Veglia, G., & Bartolomucci, A.
- Affiliations
- University of Minnesota (US)
- National Research Council (IT)
- University of North Carolina at Chapel Hill (US)
- University of Rome Tor Vergata (IT)
- Corresponding author
- Veglia, Gianluigi
- Bartolomucci, Alessandro
- ORCID
- Venue
- Structure
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 22
- Issue
- 12
- Pages
- 1744-1753
- ISSN
- 0969-2126 (ISSN-L)
- PMC
- PMC4353613
- OpenAlex
- W2095674992
- Semantic Scholar
- cebe5bfda44e8cd48293cb5aa607152db53a7fee
- Cited by
- 71
- References
- 56
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 8 · 2020: 13 · 2019: 4 · 2018: 6 · 2017: 6 · 2016: 7 · 2015: 7
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- Locations
- Structure (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health
- National Institute of Mental Health
- National Institute on Drug Abuse (R21DA025170)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK050456, R01DK102496)
- National Institute of Dental and Craniofacial Research (R01DE021996)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- TLQP-21, C3AR1, C3a receptor, G protein-coupled receptor activation, intrinsically disordered peptides, disorder-to-order transition, obesity, C-terminal amidation
- MeSH terms
- Animals, Female, Models, Molecular, Peptide Fragments, Protein Binding, Protein Conformation, Receptors, Complement, Spleen, Rats, Wistar, Adipocytes, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.